BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sands BE, Tremaine WJ, Sandborn WJ, Rutgeerts PJ, Hanauer SB, Mayer L, Targan SR, Podolsky DK. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis. 2001;7:83-88. [PMID: 11383595 DOI: 10.1097/00054725-200105000-00001] [Cited by in Crossref: 288] [Cited by in F6Publishing: 267] [Article Influence: 13.7] [Reference Citation Analysis]
Number Citing Articles
1 Dean KE, Hikaka J, Huakau JT, Walmsley RS. Infliximab or cyclosporine for acute severe ulcerative colitis: a retrospective analysis. J Gastroenterol Hepatol. 2012;27:487-492. [PMID: 22098019 DOI: 10.1111/j.1440-1746.2011.06958.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 3.3] [Reference Citation Analysis]
2 Khan HM, Mehmood F, Khan N. Optimal management of steroid-dependent ulcerative colitis. Clin Exp Gastroenterol. 2015;8:293-302. [PMID: 26648749 DOI: 10.2147/ceg.s57248] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
3 Gisbert JP, González-Lama Y, Maté J. Systematic review: Infliximab therapy in ulcerative colitis. Aliment Pharmacol Ther. 2007;25:19-37. [PMID: 17229218 DOI: 10.1111/j.1365-2036.2006.03131.x] [Cited by in Crossref: 93] [Cited by in F6Publishing: 79] [Article Influence: 6.2] [Reference Citation Analysis]
4 Sandborn WJ, Hanauer SB. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians. Am J Gastroenterol. 2002;97:2962-2972. [PMID: 12492177 DOI: 10.1111/j.1572-0241.2002.07093.x] [Cited by in Crossref: 138] [Cited by in F6Publishing: 130] [Article Influence: 7.3] [Reference Citation Analysis]
5 Ogata H, Matsui T, Nakamura M, Iida M, Takazoe M, Suzuki Y, Hibi T. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut. 2006;55:1255-1262. [PMID: 16484504 DOI: 10.1136/gut.2005.081794] [Cited by in Crossref: 290] [Cited by in F6Publishing: 233] [Article Influence: 18.1] [Reference Citation Analysis]
6 Chaudhary MA, Fan T. Cost-Effectiveness of Infliximab for the Treatment of Acute Exacerbations of Ulcerative Colitis in the Netherlands. Biol Ther. 2013;3:45-60. [PMID: 24392304 DOI: 10.1007/s13554-012-0007-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
7 Sjöberg M, Walch A, Meshkat M, Gustavsson A, Järnerot G, Vogelsang H, Hertervig E, Novacek G, Friis-Liby I, Blomquist L. Infliximab or cyclosporine as rescue therapy in hospitalized patients with steroid-refractory ulcerative colitis: a retrospective observational study. Inflamm Bowel Dis. 2012;18:212-218. [PMID: 21438096 DOI: 10.1002/ibd.21680] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 3.7] [Reference Citation Analysis]
8 Grinspan A, Kornbluth A. Positioning Therapy for Ulcerative Colitis. Curr Gastroenterol Rep 2015;17:29. [PMID: 26143627 DOI: 10.1007/s11894-015-0454-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
9 Kaur M, Targan SR. Ulcerative colitis: steroid-refractory ulcerative colitis-ciclosporin or infliximab? Nat Rev Gastroenterol Hepatol 2013;10:8-9. [PMID: 23229328 DOI: 10.1038/nrgastro.2012.235] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
10 Barta Z, Tóth L, Zeher M. Pulse cyclophosphamide therapy for inflammatory bowel disease. World J Gastroenterol 2006; 12(8): 1278-1280 [PMID: 16534885 DOI: 10.3748/wjg.v12.i8.1278] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
11 Sandborn WJ, Targan SR. Biologic therapy of inflammatory bowel disease. Gastroenterology. 2002;122:1592-1608. [PMID: 12016425 DOI: 10.1053/gast.2002.33426] [Cited by in Crossref: 226] [Cited by in F6Publishing: 198] [Article Influence: 11.3] [Reference Citation Analysis]
12 Pugliese D, Felice C, Landi R, Papa A, Guidi L, Armuzzi A. Benefit-risk assessment of golimumab in the treatment of refractory ulcerative colitis. Drug Healthc Patient Saf. 2016;8:1-7. [PMID: 26893582 DOI: 10.2147/dhps.s62649] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
13 Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, Macdonald JK, Filippini G, Skoetz N, Francis D, Lopes LC. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011;CD008794. [PMID: 21328309 DOI: 10.1002/14651858.cd008794.pub2] [Cited by in Crossref: 189] [Cited by in F6Publishing: 200] [Article Influence: 17.2] [Reference Citation Analysis]
14 Pugliese D, Felice C, Papa A, Gasbarrini A, Rapaccini GL, Guidi L, Armuzzi A. Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future. Expert Rev Clin Immunol 2017;13:223-33. [PMID: 27687496 DOI: 10.1080/1744666X.2017.1243468] [Cited by in Crossref: 32] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
15 Lago P. Ulcerative colitis: history of a successful treatment. BioDrugs 2010;24 Suppl 1:34-6. [PMID: 21175235 DOI: 10.2165/11586230-000000000-00000] [Reference Citation Analysis]
16 Rutgeerts P, van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004;126:1593-610. [DOI: 10.1053/j.gastro.2004.02.070] [Cited by in Crossref: 290] [Cited by in F6Publishing: 256] [Article Influence: 16.1] [Reference Citation Analysis]
17 Strong S, Steele SR, Boutrous M, Bordineau L, Chun J, Stewart DB, Vogel J, Rafferty JF; Clinical Practice Guidelines Committee of the American Society of Colon and Rectal Surgeons. Clinical Practice Guideline for the Surgical Management of Crohn's Disease. Dis Colon Rectum 2015;58:1021-36. [PMID: 26445174 DOI: 10.1097/DCR.0000000000000450] [Cited by in Crossref: 65] [Cited by in F6Publishing: 19] [Article Influence: 10.8] [Reference Citation Analysis]
18 Seah D, De Cruz P. Review article: the practical management of acute severe ulcerative colitis. Aliment Pharmacol Ther. 2016;43:482-513. [PMID: 26725569 DOI: 10.1111/apt.13491] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 8.3] [Reference Citation Analysis]
19 Sturm A, Fiocchi C. Life and death in the gut: more killing, less Crohn's. Gut 2002;50:148-9. [PMID: 11788550 DOI: 10.1136/gut.50.2.148] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
20 McClements D, Probert C. Managing acute severe ulcerative colitis in the hosptialised setting. Frontline Gastroenterol 2015;6:241-5. [PMID: 28839817 DOI: 10.1136/flgastro-2014-100459] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
21 Williams CJ, Peyrin-Biroulet L, Ford AC. Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-α therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2014;39:447-58. [PMID: 24444171 DOI: 10.1111/apt.12624] [Cited by in Crossref: 105] [Cited by in F6Publishing: 95] [Article Influence: 13.1] [Reference Citation Analysis]
22 Ford AC, Peyrin-biroulet L. Opportunistic Infections With Anti-Tumor Necrosis Factor-α Therapy in Inflammatory Bowel Disease: Meta-Analysis of Randomized Controlled Trials. American Journal of Gastroenterology 2013;108:1268-76. [DOI: 10.1038/ajg.2013.138] [Cited by in Crossref: 226] [Cited by in F6Publishing: 194] [Article Influence: 25.1] [Reference Citation Analysis]
23 Tsiodras S, Samonis G, Boumpas DT, Kontoyiannis DP. Fungal Infections Complicating Tumor Necrosis Factor α Blockade Therapy. Mayo Clinic Proceedings 2008;83:181-94. [DOI: 10.4065/83.2.181] [Cited by in Crossref: 37] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
24 Ljung T, Karlén P, Schmidt D, Hellström PM, Lapidus A, Janczewska I, Sjöqvist U, Löfberg R. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut. 2004;53:849-853. [PMID: 15138212 DOI: 10.1136/gut.2003.018515] [Cited by in Crossref: 206] [Cited by in F6Publishing: 190] [Article Influence: 11.4] [Reference Citation Analysis]
25 Miehsler W, Novacek G, Wenzl H, Vogelsang H, Knoflach P, Kaser A, Dejaco C, Petritsch W, Kapitan M, Maier H. A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease. J Crohns Colitis. 2010;4:221-256. [PMID: 21122513 DOI: 10.1016/j.crohns.2009.12.001] [Cited by in Crossref: 60] [Cited by in F6Publishing: 55] [Article Influence: 5.0] [Reference Citation Analysis]
26 Laharie D, Bourreille A, Branche J, Allez M, Bouhnik Y, Filippi J, Zerbib F, Savoye G, Nachury M, Moreau J. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet. 2012;380:1909-1915. [PMID: 23063316 DOI: 10.1016/s0140-6736(12)61084-8] [Cited by in Crossref: 342] [Cited by in F6Publishing: 124] [Article Influence: 34.2] [Reference Citation Analysis]
27 Fausel R, Afzali A. Biologics in the management of ulcerative colitis - comparative safety and efficacy of TNF-α antagonists. Ther Clin Risk Manag 2015;11:63-73. [PMID: 25609972 DOI: 10.2147/TCRM.S55506] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
28 Creed TJ, Probert CS, Norman MN, Moorghen M, Shepherd NA, Hearing SD, Dayan CM; BASBUC INVESTIGATORS. Basiliximab for the treatment of steroid-resistant ulcerative colitis: further experience in moderate and severe disease. Aliment Pharmacol Ther. 2006;23:1435-1442. [PMID: 16669958 DOI: 10.1111/j.1365-2036.2006.02904.x] [Cited by in Crossref: 71] [Cited by in F6Publishing: 57] [Article Influence: 4.4] [Reference Citation Analysis]
29 Patel P, Yarur A, Dalal S, Sakuraba A, Rubin DT, Hanauer SB, Hanan I, Raffals LH, Cohen RD, Pekow J. Clinical Response and Complications are not Associated with Drug Levels in Patients with Severe Ulcerative Colitis on IV Cyclosporine Induction Therapy. Inflamm Bowel Dis 2018;24:1291-7. [PMID: 29506124 DOI: 10.1093/ibd/izx105] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
30 Viscido A, Papi C, Latella G, Frieri G. Has infliximab influenced the course and prognosis of acute severe ulcerative colitis? Biologics 2019;13:23-31. [PMID: 31114154 DOI: 10.2147/BTT.S179006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
31 Alzafiri R, Holcroft CA, Malolepszy P, Cohen A, Szilagyi A. Infliximab therapy for moderately severe Crohn's disease and ulcerative colitis: a retrospective comparison over 6 years. Clin Exp Gastroenterol 2011;4:9-17. [PMID: 21694867 DOI: 10.2147/CEG.S16168] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
32 Aberra FN, Lichtenstein GR. Infliximab in ulcerative colitis. Gastroenterol Clin North Am 2006;35:821-36. [PMID: 17129815 DOI: 10.1016/j.gtc.2006.09.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
33 Garud S, Brown A, Cheifetz A, Levitan EB, Kelly CP. Meta-analysis of the placebo response in ulcerative colitis. Dig Dis Sci 2008;53:875-91. [PMID: 17934839 DOI: 10.1007/s10620-007-9954-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
34 Talley NJ, Abreu MT, Achkar JP, Bernstein CN, Dubinsky MC, Hanauer SB, Kane SV, Sandborn WJ, Ullman TA, Moayyedi P. An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol. 2011;106 Suppl 1:S2-S25; quiz S26. [PMID: 21472012 DOI: 10.1038/ajg.2011.58] [Cited by in Crossref: 177] [Cited by in F6Publishing: 165] [Article Influence: 16.1] [Reference Citation Analysis]
35 Chang JC, Cohen RD. Medical management of severe ulcerative colitis. Gastroenterology Clinics of North America 2004;33:235-50. [DOI: 10.1016/j.gtc.2004.02.005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
36 McGinnis JK, Murray KF. Infliximab for ulcerative colitis in children and adolescents. J Clin Gastroenterol. 2008;42:875-879. [PMID: 18645529 DOI: 10.1097/mcg.0b013e3181354417] [Cited by in Crossref: 30] [Cited by in F6Publishing: 8] [Article Influence: 2.1] [Reference Citation Analysis]
37 Sjöberg M, Magnuson A, Björk J, Benoni C, Almer S, Friis-Liby I, Hertervig E, Olsson M, Karlén P, Eriksson A. Infliximab as rescue therapy in hospitalised patients with steroid-refractory acute ulcerative colitis: a long-term follow-up of 211 Swedish patients. Aliment Pharmacol Ther. 2013;38:377-387. [PMID: 23799948 DOI: 10.1111/apt.12387] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 6.1] [Reference Citation Analysis]
38 Ardizzone S, Bianchi Porro G. Inflammatory bowel disease: new insights into pathogenesis and treatment. J Intern Med. 2002;252:475-496. [PMID: 12472908 DOI: 10.1046/j.1365-2796.2002.01067.x] [Cited by in Crossref: 114] [Cited by in F6Publishing: 103] [Article Influence: 6.0] [Reference Citation Analysis]
39 Kohn A, Daperno M, Armuzzi A, Cappello M, Biancone L, Orlando A, Viscido A, Annese V, Riegler G, Meucci G. Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up. Aliment Pharmacol Ther. 2007;26:747-756. [PMID: 17697208 DOI: 10.1111/j.1365-2036.2007.03415.x] [Cited by in Crossref: 116] [Cited by in F6Publishing: 107] [Article Influence: 7.7] [Reference Citation Analysis]
40 Baldassano RN. Is There Still a Role for Cyclosporine in the Treatment of Inflammatory Bowel Disease?: . Inflammatory Bowel Diseases 2003;9:202-4. [DOI: 10.1097/00054725-200305000-00010] [Reference Citation Analysis]
41 Chan HC, Ng SC. Emerging biologics in inflammatory bowel disease. J Gastroenterol. 2017;52:141-150. [PMID: 27832357 DOI: 10.1007/s00535-016-1283-0] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 6.5] [Reference Citation Analysis]
42 Kohn A. Is there a role for infliximab in severe ulcerative colitis?: The European experience: . Inflammatory Bowel Diseases 2008;14:S234-5. [DOI: 10.1002/ibd.20665] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
43 Biancone L, Calabrese E, Petruzziello C, Pallone F. Treatment with biologic therapies and the risk of cancer in patients with IBD. Nat Rev Gastroenterol Hepatol 2007;4:78-91. [DOI: 10.1038/ncpgasthep0695] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 2.4] [Reference Citation Analysis]
44 Danese S, Angelucci E, Malesci A, Caprilli R. Biological agents for ulcerative colitis: hypes and hopes. Med Res Rev. 2008;28:201-218. [PMID: 17464967 DOI: 10.1002/med.20103] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
45 Murdoch T, O'Donnell S, Silverberg MS, Panaccione R. Biomarkers as potential treatment targets in inflammatory bowel disease: A systematic review. Can J Gastroenterol Hepatol 2015;29:203-8. [PMID: 25965441 DOI: 10.1155/2015/389548] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
46 Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:644-659, quiz 660. [PMID: 21407183 DOI: 10.1038/ajg.2011.73] [Cited by in Crossref: 374] [Cited by in F6Publishing: 353] [Article Influence: 34.0] [Reference Citation Analysis]
47 Fornaro R, Caratto M, Barbruni G, Fornaro F, Salerno A, Giovinazzo D, Sticchi C, Caratto E. Surgical and medical treatment in patients with acute severe ulcerative colitis. J Dig Dis. 2015;16:558-567. [PMID: 26315728 DOI: 10.1111/1751-2980.12278] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
48 High WA, Muldrow ME, Fitzpatrick JE. Cutaneous lupus erythematosus induced by infliximab. Journal of the American Academy of Dermatology 2005;52:E7-8. [DOI: 10.1016/s0190-9622(03)00869-7] [Cited by in Crossref: 13] [Article Influence: 0.8] [Reference Citation Analysis]
49 Siveke JT, Folwaczny C. Medical approaches and future options in chronic active ulcerative colitis. Int J Colorectal Dis 2004;19:297-307. [PMID: 14727131 DOI: 10.1007/s00384-003-0569-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
50 Cottone M, Mocciaro F, Modesto I. Infliximab and ulcerative colitis. Expert Opinion on Biological Therapy 2006;6:401-8. [DOI: 10.1517/14712598.6.4.401] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
51 Lightner AL, Vogel JD, Carmichael JC, Keller DS, Shah SA, Mahadevan U, Kane SV, Paquette IM, Steele SR, Feingold DL. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Surgical Management of Crohn's Disease. Dis Colon Rectum. 2020;63:1028-1052. [PMID: 32692069 DOI: 10.1097/dcr.0000000000001716] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
52 Regueiro M, Loftus EV, Steinhart AH, Cohen RD. Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials. Inflamm Bowel Dis. 2006;12:979-994. [PMID: 17012969 DOI: 10.1097/01.mib.0000231495.92013.5e] [Cited by in Crossref: 77] [Cited by in F6Publishing: 65] [Article Influence: 5.1] [Reference Citation Analysis]
53 Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol. 2019;114:384-413. [PMID: 30840605 DOI: 10.14309/ajg.0000000000000152] [Cited by in Crossref: 300] [Cited by in F6Publishing: 254] [Article Influence: 100.0] [Reference Citation Analysis]
54 Hart AL, Ng SC. Review article: the optimal medical management of acute severe ulcerative colitis. Aliment Pharmacol Ther 2010;32:615-27. [PMID: 20626381 DOI: 10.1111/j.1365-2036.2010.04392.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
55 Selvaggi F, Pellino G, Ghezzi G, Corona D, Riegler G, Delaini GG. A think tank of the Italian Society of Colorectal Surgery (SICCR) on the surgical treatment of inflammatory bowel disease using the Delphi method: ulcerative colitis. Tech Coloproctol 2015;19:627-38. [PMID: 26386867 DOI: 10.1007/s10151-015-1367-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
56 Guthery SL, Dong L, Dean MJ, Holubkov R. US estimates of hospitalized pediatric patients with ulcerative colitis: Implications for multicenter clinical studies: . Inflammatory Bowel Diseases 2008;14:1253-8. [DOI: 10.1002/ibd.20521] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
57 Chaparro M, Burgueño P, Iglesias E, Panés J, Muñoz F, Bastida G, Castro L, Jiménez C, Mendoza JL, Barreiro-de Acosta M, Gómez Senent S, Gomollón F, Calvet X, García-planella E, Gómez M, Hernández V, Hinojosa J, Mañosa M, Pérez Nyssen O, Gisbert JP. Infliximab salvage therapy after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: a multicentre study: Infliximab after ciclosporin failure in ulcerative colitis. Alimentary Pharmacology & Therapeutics 2012;35:275-83. [DOI: 10.1111/j.1365-2036.2011.04934.x] [Cited by in Crossref: 83] [Cited by in F6Publishing: 62] [Article Influence: 7.5] [Reference Citation Analysis]
58 Kim EH, Kim DH, Park SJ, Hong SP, Kim TI, Kim WH, Cheon JH. Infliximab versus Cyclosporine Treatment for Severe Corticosteroid-Refractory Ulcerative Colitis: A Korean, Retrospective, Single Center Study. Gut Liver 2015;9:601-6. [PMID: 25473080 DOI: 10.5009/gnl14120] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
59 Baudet A, Rahmi G, Bretagne AL, Gloro R, Justum AM, Reimund JM. Severe ulcerative colitis: present medical treatment strategies. Expert Opin Pharmacother. 2008;9:447-457. [PMID: 18220494 DOI: 10.1517/14656566.9.3.447] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
60 Cuffari C, Present DH, Bayless TM, Lichtenstein GR. Optimizing therapy in patients with pancolitis. Inflamm Bowel Dis 2005;11:937-46. [PMID: 16189424 DOI: 10.1097/01.mib.0000179469.86500.ac] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
61 Jairath V, Zou GY, Parker CE, MacDonald JK, AlAmeel T, Al Beshir M, Almadi MA, Al-Taweel T, Atkinson NS, Biswas S, Chapman T, Dulai PS, Glaire MA, Hoekman DR, Koutsoumpas A, Minas E, Mosli MH, Samaan M, Khanna R, Travis S, D'Haens G, Sandborn WJ, Feagan BG. Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis. Cochrane Database Syst Rev 2017;9:CD011572. [PMID: 28886205 DOI: 10.1002/14651858.CD011572.pub2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
62 Monteleone G, Pallone F, Caprioli F. Investigational cytokine-targeted therapies for ulcerative colitis. Expert Opin Investig Drugs 2013;22:1123-32. [PMID: 23802627 DOI: 10.1517/13543784.2013.813931] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
63 Ferrante M, Vermeire S, Katsanos KH, Noman M, Van Assche G, Schnitzler F, Arijs I, De Hertogh G, Hoffman I, Geboes JK. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis. 2007;13:123-128. [PMID: 17206703 DOI: 10.1002/ibd.20054] [Cited by in Crossref: 126] [Cited by in F6Publishing: 119] [Article Influence: 8.4] [Reference Citation Analysis]
64 Strong SA. Management of acute colitis and toxic megacolon. Clin Colon Rectal Surg 2010;23:274-84. [PMID: 22131898 DOI: 10.1055/s-0030-1268254] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
65 Probert CS, Hearing SD, Schreiber S, Kühbacher T, Ghosh S, Arnott ID, Forbes A. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut. 2003;52:998-1002. [PMID: 12801957 DOI: 10.1136/gut.52.7.998] [Cited by in Crossref: 233] [Cited by in F6Publishing: 224] [Article Influence: 12.3] [Reference Citation Analysis]
66 Choi CH, Kim YH, Kim YS, Ye BD, Lee KM, Lee BI, Jung SA, Kim WH, Lee H; IBD Study Group of the Korean Association for the Study of Intestinal Diseases. [Guidelines for the management of ulcerative colitis]. Korean J Gastroenterol. 2012;59:118-140. [PMID: 22387836 DOI: 10.4166/kjg.2012.59.2.118] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
67 Caviglia R, Ribolsi M, Rizzi M, Emerenziani S, Annunziata ML, Cicala M. Maintenance of remission with infliximab in inflammatory bowel disease: Efficacy and safety long-term follow-up. World J Gastroenterol 2007; 13(39): 5238-5244 [PMID: 17876895 DOI: 10.3748/wjg.v13.i39.5238] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
68 Navaneethan U, Shen B. Pros and cons of medical management of ulcerative colitis. Clin Colon Rectal Surg 2010;23:227-38. [PMID: 22131893 DOI: 10.1055/s-0030-1268249] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
69 Bitton A, Buie D, Enns R, Feagan BG, Jones JL, Marshall JK, Whittaker S, Griffiths AM, Panaccione R; Canadian Association of Gastroenterology Severe Ulcerative Colitis Consensus Group. Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements. Am J Gastroenterol. 2012;107:179-194; author reply 195. [PMID: 22108451 DOI: 10.1038/ajg.2011.386] [Cited by in Crossref: 106] [Cited by in F6Publishing: 92] [Article Influence: 9.6] [Reference Citation Analysis]
70 Sofia MA, Rubin DT. The Impact of Therapeutic Antibodies on the Management of Digestive Diseases: History, Current Practice, and Future Directions. Dig Dis Sci 2017;62:833-42. [PMID: 28197743 DOI: 10.1007/s10620-017-4479-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
71 Biondi A, Zoccali M, Costa S, Troci A, Contessini-Avesani E, Fichera A. Surgical treatment of ulcerative colitis in the biologic therapy era. World J Gastroenterol 2012; 18(16): 1861-1870 [PMID: 22563165 DOI: 10.3748/wjg.v18.i16.1861] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 31] [Article Influence: 2.7] [Reference Citation Analysis]
72 Krause I, Valesini G, Scrivo R, Shoenfeld Y. Autoimmune aspects of cytokine and anticytokine therapies. Am J Med. 2003;115:390-397. [PMID: 14553875 DOI: 10.1016/s0002-9343(03)00390-5] [Cited by in Crossref: 56] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
73 Truong A, Zaghiyan KN, Mirocha J, Melmed GY, McGovern DPB, Syal G, Ha CY, Targan SR, Fleshner PR. Antitumour necrosis factor therapy is associated with de novo Crohn's disease after ileal pouch-anal anastomosis. Colorectal Dis 2021;23:2416-24. [PMID: 34157179 DOI: 10.1111/codi.15772] [Reference Citation Analysis]
74 Eidelwein AP, Cuffari C, Abadom V, Oliva-Hemker M. Infliximab efficacy in pediatric ulcerative colitis. Inflamm Bowel Dis. 2005;11:213-218. [PMID: 15735427 DOI: 10.1097/01.mib.0000160803.44449.a5] [Cited by in Crossref: 73] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
75 Russell GH, Katz AJ. Infliximab Is Effective in Acute but not Chronic Childhood Ulcerative Colitis: . Journal of Pediatric Gastroenterology and Nutrition 2004;39:166-70. [DOI: 10.1097/00005176-200408000-00008] [Cited by in Crossref: 48] [Cited by in F6Publishing: 39] [Article Influence: 2.7] [Reference Citation Analysis]
76 Hoentjen F, Sakuraba A, Hanauer S. Update on the Management of Ulcerative Colitis. Curr Gastroenterol Rep 2011;13:475-85. [DOI: 10.1007/s11894-011-0216-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
77 Travis S, Stange E, Lémann M, Øresland T, Bemelman W, Chowers Y, Colombel J, D'haens G, Ghosh S, Marteau P, Kruis W, Mortensen N, Penninckx F, Gassull M. European evidence-based Consensus on the management of ulcerative colitis: Current management. Journal of Crohn's and Colitis 2008;2:24-62. [DOI: 10.1016/j.crohns.2007.11.002] [Cited by in Crossref: 378] [Cited by in F6Publishing: 325] [Article Influence: 27.0] [Reference Citation Analysis]
78 Arora Z, Shen B. Biological therapy for ulcerative colitis. Gastroenterol Rep (Oxf) 2015;3:103-9. [PMID: 25344680 DOI: 10.1093/gastro/gou070] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
79 Huang X, Lv B, Jin H, Zhang S. A meta-analysis of the therapeutic effects of tumor necrosis factor-α blockers on ulcerative colitis. Eur J Clin Pharmacol 2011;67:759-66. [DOI: 10.1007/s00228-011-1079-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
80 Actis G. Infliximab for Ulcerative Colitis. Am J Gastroenterology 2003;98:709-709. [DOI: 10.1111/j.1572-0241.2003.07312.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
81 Swaroop PP. Inflammatory bowel diseases in the elderly. Clin Geriatr Med. 2007;23:809-821, vi. [PMID: 17923339 DOI: 10.1016/j.cger.2007.06.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
82 Hochberg MC, Lebwohl MG, Plevy SE, Hobbs KF, Yocum DE. The Benefit/Risk Profile of TNF-Blocking Agents: Findings of a Consensus Panel. Seminars in Arthritis and Rheumatism 2005;34:819-36. [DOI: 10.1016/j.semarthrit.2004.11.006] [Cited by in Crossref: 140] [Cited by in F6Publishing: 118] [Article Influence: 8.2] [Reference Citation Analysis]
83 D'Haens G. Infliximab for ulcerative colitis: finally some answers. Gastroenterology 2005;128:2161-4. [PMID: 15940648 DOI: 10.1053/j.gastro.2005.04.019] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
84 Travassos WJ, Cheifetz AS. Infliximab: Use in Inflammatory Bowel Disease. Curr Treat Options Gastroenterol. 2005;8:187-196. [PMID: 15913508 DOI: 10.1007/s11938-005-0011-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 1.3] [Reference Citation Analysis]
85 Daperno M, Sostegni R, Scaglione N, Ercole E, Rigazio C, Rocca R, Pera A. Outcome of a conservative approach in severe ulcerative colitis. Dig Liver Dis. 2004;36:21-28. [PMID: 14971812 DOI: 10.1016/j.dld.2003.04.001] [Cited by in Crossref: 64] [Cited by in F6Publishing: 54] [Article Influence: 3.6] [Reference Citation Analysis]
86 Lawson MM, Thomas AG, Akobeng AK. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006;CD005112. [PMID: 16856078 DOI: 10.1002/14651858.cd005112] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
87 Sohi S, Cohen RD. Management of refractory ulcerative colitis. Curr Treat Options Gastro 2006;9:234-45. [DOI: 10.1007/s11938-006-0042-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
88 Eshuis EJ, Bemelman WA, Stokkers PC. Infliximab for the treatment of ulcerative colitis. Expert Review of Gastroenterology & Hepatology 2014;3:219-29. [DOI: 10.1586/egh.09.19] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
89 Comerford LW, Bickston SJ. Treatment of luminal and fistulizing Crohn's disease with infliximab. Gastroenterol Clin North Am. 2004;33:387-406, xi. [PMID: 15177545 DOI: 10.1016/j.gtc.2004.02.014] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
90 Rutgeerts P. Infliximab for ulcerative colitis: the need for adequately powered placebo-controlled trials. Am J Gastroenterology 2002;97:2488-9. [DOI: 10.1111/j.1572-0241.2002.06049.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
91 Dignass A, Lindsay JO, Sturm A, Windsor A, Colombel JF, Allez M, d'Haens G, d'Hoore A, Mantzanaris G, Novacek G, Öresland T, Reinisch W, Sans M, Stange E, Vermeire S, Travis S, van Assche G. [Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management (Spanish version)]. Rev Gastroenterol Mex 2015;80:32-73. [PMID: 25769217 DOI: 10.1016/j.rgmx.2014.10.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
92 Dong C, Metzger M, Holsbø E, Perduca V, Carbonnel F. Systematic review with meta-analysis: mortality in acute severe ulcerative colitis. Aliment Pharmacol Ther 2020;51:8-33. [DOI: 10.1111/apt.15592] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
93 Vasudevan A, Gibson PR, Langenberg DRV. Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told? World J Gastroenterol 2017; 23(35): 6385-6402 [PMID: 29085188 DOI: 10.3748/wjg.v23.i35.6385] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 15] [Article Influence: 4.2] [Reference Citation Analysis]
94 Papachristou GI, Plevy S. Novel biologics in inflammatory bowel disease. Gastroenterol Clin North Am 2004;33:251-69, ix. [PMID: 15177537 DOI: 10.1016/j.gtc.2004.02.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
95 Renna S, Cottone M, Orlando A. Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease. World J Gastroenterol 2014; 20(29): 9675-9690 [PMID: 25110407 DOI: 10.3748/wjg.v20.i29.9675] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 38] [Article Influence: 5.6] [Reference Citation Analysis]
96 Seo SH, Unno T, Park SE, Kim EJ, Lee YM, Na CS, Son HS. Korean Traditional Medicine (Jakyakgamcho-tang) Ameliorates Colitis by Regulating Gut Microbiota. Metabolites 2019;9:E226. [PMID: 31615012 DOI: 10.3390/metabo9100226] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
97 Sandborn WJ, Rutgeerts P, Feagan BG, Reinisch W, Olson A, Johanns J, Lu J, Horgan K, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Colectomy Rate Comparison After Treatment of Ulcerative Colitis With Placebo or Infliximab. Gastroenterology 2009;137:1250-60. [DOI: 10.1053/j.gastro.2009.06.061] [Cited by in Crossref: 312] [Cited by in F6Publishing: 291] [Article Influence: 24.0] [Reference Citation Analysis]
98 Roda G, Marocchi M, Sartini A, Roda E. Cytokine Networks in Ulcerative Colitis. Ulcers 2011;2011:1-5. [DOI: 10.1155/2011/391787] [Cited by in Crossref: 24] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
99 Hussain SW, Pardi DS. Inflammatory bowel disease in the elderly. Drugs Aging. 2010;27:617-624. [PMID: 20658790 DOI: 10.2165/11537340-000000000-00000] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
100 Gisbert JP, Chaparro M. Acute severe ulcerative colitis: State of the art treatment. Best Pract Res Clin Gastroenterol 2018;32-33:59-69. [PMID: 30060940 DOI: 10.1016/j.bpg.2018.05.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
101 Rutgeerts P. A critical assessment of new therapies in inflammatory bowel disease. J Gastroenterol Hepatol. 2002;17 Suppl:S176-S185. [PMID: 12000604 DOI: 10.1046/j.1440-1746.17.s1.1.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 2.0] [Reference Citation Analysis]
102 Ringheanu M, Markowitz J. Inflammatory bowel disease in children. Curr Treat Options Gastro 2002;5:181-96. [DOI: 10.1007/s11938-002-0040-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
103 Staros EB. Molecular Discoveries Alter Our View of Inflammatory Bowel Disease: A Review From Scientific, Clinical, and Laboratory Perspectives. Am J Clin Pathol 2003;119:524-39. [DOI: 10.1309/7w3etl9nq9rhhx61] [Cited by in Crossref: 7] [Article Influence: 0.4] [Reference Citation Analysis]
104 Guo C, Wu K, Liang X, Liang Y, Li R. Infliximab clinically treating ulcerative colitis: A systematic review and meta-analysis. Pharmacol Res 2019;148:104455. [PMID: 31562896 DOI: 10.1016/j.phrs.2019.104455] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
105 Williams JG, Alam MF, Alrubaiy L, Clement C, Cohen D, Grey M, Hilton M, Hutchings HA, Longo M, Morgan JM, Rapport FL, Seagrove AC, Watkins A. Comparison Of iNfliximab and ciclosporin in STeroid Resistant Ulcerative Colitis: pragmatic randomised Trial and economic evaluation (CONSTRUCT). Health Technol Assess 2016;20:1-320. [PMID: 27329657 DOI: 10.3310/hta20440] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 7.3] [Reference Citation Analysis]
106 Escher JC, Taminiau JAJM, Nieuwenhuis EES, Büller HA, Grand RJ. Treatment of Inflammatory Bowel Disease in Childhood: Best Available Evidence: . Inflammatory Bowel Diseases 2003;9:34-58. [DOI: 10.1097/00054725-200301000-00006] [Cited by in Crossref: 93] [Cited by in F6Publishing: 68] [Article Influence: 4.9] [Reference Citation Analysis]
107 O'Toole A, Moss AC. Optimizing Biologic Agents in Ulcerative Colitis and Crohn's Disease. Curr Gastroenterol Rep 2015;17:32. [PMID: 26188882 DOI: 10.1007/s11894-015-0453-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
108 Daperno M, Sostegni R, Rocca R, Rigazio C, Scaglione N, Castellino F, Ercole E, Pera A. Medical treatment of severe ulcerative colitis: REVIEW: MEDICAL TREATMENT OF SEVERE ULCERATIVE COLITIS. Alimentary Pharmacology & Therapeutics 2002;16:7-12. [DOI: 10.1046/j.1365-2036.16.s4.2.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 1.5] [Reference Citation Analysis]
109 Peyrin-biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, D'haens G, Dotan I, Dubinsky M, Feagan B, Fiorino G, Gearry R, Krishnareddy S, Lakatos PL, Loftus EV, Marteau P, Munkholm P, Murdoch TB, Ordás I, Panaccione R, Riddell RH, Ruel J, Rubin DT, Samaan M, Siegel CA, Silverberg MS, Stoker J, Schreiber S, Travis S, Van Assche G, Danese S, Panes J, Bouguen G, O'donnell S, Pariente B, Winer S, Hanauer S, Colombel J-. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. American Journal of Gastroenterology 2015;110:1324-38. [DOI: 10.1038/ajg.2015.233] [Cited by in Crossref: 937] [Cited by in F6Publishing: 820] [Article Influence: 133.9] [Reference Citation Analysis]
110 Bouhnik Y, Alvès A, Beau P, Carbonnel F, Lévy P. Traitement de la rectocolite ulcéro-hémorragique dans sa forme grave. Gastroentérologie Clinique et Biologique 2004;28:984-91. [DOI: 10.1016/s0399-8320(04)95176-7] [Cited by in Crossref: 6] [Article Influence: 0.3] [Reference Citation Analysis]
111 Battat R, Hemperly A, Truong S, Whitmire N, Boland BS, Dulai PS, Holmer AK, Nguyen NH, Singh S, Vande Casteele N, Sandborn WJ. Baseline Clearance of Infliximab Is Associated With Requirement for Colectomy in Patients With Acute Severe Ulcerative Colitis. Clin Gastroenterol Hepatol 2021;19:511-518.e6. [PMID: 32348905 DOI: 10.1016/j.cgh.2020.03.072] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
112 Huang XL, Xu J, Zhang XH, Qiu BY, Peng L, Zhang M, Gan HT. PI3K/Akt signaling pathway is involved in the pathogenesis of ulcerative colitis. Inflamm Res. 2011;60:727-734. [PMID: 21442372 DOI: 10.1007/s00011-011-0325-6] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 4.6] [Reference Citation Analysis]
113 Sobrado CW, Sobrado LF. MANAGEMENT OF ACUTE SEVERE ULCERATIVE COLITIS: A CLINICAL UPDATE. Arq Bras Cir Dig 2016;29:201-5. [PMID: 27759787 DOI: 10.1590/0102-6720201600030017] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
114 Lichtenstein GR, Rutgeerts P, Sandborn WJ, Sands BE, Diamond RH, Blank M, Montello J, Tang L, Cornillie F, Colombel JF. A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol. 2012;107:1051-1063. [PMID: 22613901 DOI: 10.1038/ajg.2012.89] [Cited by in Crossref: 137] [Cited by in F6Publishing: 130] [Article Influence: 13.7] [Reference Citation Analysis]
115 Järnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlén P, Grännö C, Vilien M, Ström M, Danielsson A, Verbaan H. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005;128:1805-1811. [PMID: 15940615 DOI: 10.1053/j.gastro.2005.03.003] [Cited by in Crossref: 734] [Cited by in F6Publishing: 651] [Article Influence: 43.2] [Reference Citation Analysis]
116 Sebastian S, Myers S, Nadir S, Subramanian S. Systematic Review: Efficacy and Safety of Accelerated Induction Regimes in Infliximab Rescue Therapy for Hospitalized Patients with Acute Severe Colitis. Dig Dis Sci. 2019;64:1119-1128. [PMID: 30535888 DOI: 10.1007/s10620-018-5407-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
117 Fan W, Zhang S, Hu J, Liu B, Wen L, Gong M, Wang G, Yang L, Chen Y, Chen H, Guo H, Zhang D. Aberrant Brain Function in Active-Stage Ulcerative Colitis Patients: A Resting-State Functional MRI Study. Front Hum Neurosci 2019;13:107. [PMID: 31001097 DOI: 10.3389/fnhum.2019.00107] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
118 Arnott ID, McDonald D, Williams A, Ghosh S. Clinical use of Infliximab in Crohn's disease: the Edinburgh experience. Aliment Pharmacol Ther. 2001;15:1639-1646. [PMID: 11564005 DOI: 10.1046/j.1365-2036.2001.01092.x] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 2.7] [Reference Citation Analysis]
119 Sofia MA, Rubin DT. Current approaches for optimizing the benefit of biologic therapy in ulcerative colitis. Therap Adv Gastroenterol 2016;9:548-59. [PMID: 27366223 DOI: 10.1177/1756283X16643242] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
120 Thukral C, Cheifetz A, Peppercorn MA. Anti-tumour necrosis factor therapy for ulcerative colitis: evidence to date. Drugs 2006;66:2059-65. [PMID: 17112300 DOI: 10.2165/00003495-200666160-00002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
121 Ljung T, Thomsen OØ, Vatn M, Karlén P, Karlsen LN, Tysk C, Nilsson SU, Kilander A, Gillberg R, Grip O, Lindgren S, Befrits R, Löfberg R. Granulocyte, monocyte/macrophage apheresis for inflammatory bowel disease: the first 100 patients treated in Scandinavia. Scand J Gastroenterol 2007;42:221-7. [PMID: 17327942 DOI: 10.1080/00365520600979369] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]
122 D'Haens GR, van Deventer S. 25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future. Gut 2021;70:1396-405. [PMID: 33431575 DOI: 10.1136/gutjnl-2019-320022] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
123 Nakamura K, Honda K, Mizutani T, Akiho H, Harada N. Novel strategies for the treatment of inflammatory bowel disease: Selective inhibition of cytokines and adhesion molecules. World J Gastroenterol 2006; 12(29): 4628-4635 [PMID: 16937430 DOI: 10.3748/wjg.v12.i29.4628] [Cited by in CrossRef: 74] [Cited by in F6Publishing: 71] [Article Influence: 4.6] [Reference Citation Analysis]
124 Ponsky T, Hindle A, Sandler A. Inflammatory bowel disease in the pediatric patient. Surg Clin North Am. 2007;87:643-658. [PMID: 17560417 DOI: 10.1016/j.suc.2007.03.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
125 Kohn A, Prantera C, Pera A, Cosintino R, Sostegni R, Daperno M. Anti-tumour necrosis factor alpha (infliximab) in the treatment of severe ulcerative colitis: result of an open study on 13 patients. Dig Liver Dis. 2002;34:626-630. [PMID: 12405248 DOI: 10.1016/s1590-8658(02)80204-3] [Cited by in Crossref: 59] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
126 Levesque BG, Sandborn WJ. Infliximab versus ciclosporin in severe ulcerative colitis. Lancet 2012;380:1887-8. [PMID: 23063315 DOI: 10.1016/S0140-6736(12)61259-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
127 Sandborn WJ. Is there a role for infliximab in the treatment of severe ulcerative colitis?: the American experience. Inflamm Bowel Dis 2008;14 Suppl 2:S232-3. [PMID: 18816658 DOI: 10.1002/ibd.20674] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
128 Bonovas S, Fiorino G, Allocca M, Lytras T, Nikolopoulos GK, Peyrin-Biroulet L, Danese S. Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis. Clin Gastroenterol Hepatol 2016; 14: 1385-1397. e10. [PMID: 27189910 DOI: 10.1016/j.cgh.2016.04.039] [Cited by in Crossref: 179] [Cited by in F6Publishing: 159] [Article Influence: 29.8] [Reference Citation Analysis]
129 Tanida S, Mizoshita T, Ozeki K, Katano T, Kataoka H, Kamiya T, Joh T. Advances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2. World J Gastroenterol 2015; 21(29): 8776-8786 [PMID: 26269667 DOI: 10.3748/wjg.v21.i29.8776] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
130 Mahadevan U, Terdiman JP, Aron J, Jacobsohn S, Turek P. Infliximab and semen quality in men with inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:395-399. [PMID: 15803031 DOI: 10.1097/01.mib.0000164023.10848.c4] [Cited by in Crossref: 89] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
131 Braun J, Sieper J. Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches. Arthritis Res 2002;4:307-21. [PMID: 12223105 DOI: 10.1186/ar592] [Cited by in Crossref: 81] [Cited by in F6Publishing: 69] [Article Influence: 4.1] [Reference Citation Analysis]
132 Hindryckx P, Baert F, Hart A, Magro F, Armuzzi A, Peyrin-biroulet L; the Clinical Trial Committee Clincom of the European Crohn’s and Colitis Organisation (ECCO). Clinical Trials in Ulcerative Colitis: A Historical Perspective. ECCOJC 2015;9:580-8. [DOI: 10.1093/ecco-jcc/jjv074] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 4.6] [Reference Citation Analysis]
133 Papadakis KA, Treyzon L, Abreu MT, Fleshner PR, Targan SR, Vasiliauskas EA. Infliximab in the treatment of medically refractory indeterminate colitis: INFLIXIMAB FOR INDETERMINATE COLITIS. Alimentary Pharmacology & Therapeutics 2003;18:741-7. [DOI: 10.1046/j.1365-2036.2003.01739.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 1.6] [Reference Citation Analysis]
134 Mamula P, Markowitz JE, Brown KA, Hurd LB, Piccoli DA, Baldassano RN. Infliximab as a Novel Therapy for Pediatric Ulcerative Colitis: . Journal of Pediatric Gastroenterology and Nutrition 2002;34:307-11. [DOI: 10.1097/00005176-200203000-00017] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 2.8] [Reference Citation Analysis]
135 Gearry RB, Falvey JD. Rescue therapy for steroid refractory acute severe ulcerative colitis: more choice, better outcomes? J Gastroenterol Hepatol 2012;27:417-8. [PMID: 22353345 DOI: 10.1111/j.1440-1746.2012.07063.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
136 Zhou Y, Huang Y. Inflammatory bowel disease in Chinese children: A retrospective analysis of 49 cases. Exp Ther Med 2016;12:3363-8. [PMID: 27882164 DOI: 10.3892/etm.2016.3756] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
137 Lawrance IC. Early investigational TNF receptor antagonists for the treatment of ulcerative colitis. Expert Opin Investig Drugs 2015;24:761-8. [PMID: 25719407 DOI: 10.1517/13543784.2015.1020371] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
138 Mortensen C, Caspersen S, Christensen NL, Svenningsen L, Thorsgaard N, Christensen LA, Bendtsen F. Treatment of acute ulcerative colitis with infliximab, a retrospective study from three Danish hospitals. J Crohns Colitis. 2011;5:28-33. [PMID: 21272801 DOI: 10.1016/j.crohns.2010.09.004] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
139 Sood A, Midha V, Sharma S, Sood N, Bansal M, Thara A, Khanna P. Infliximab in patients with severe steroid-refractory ulcerative colitis: Indian experience. Indian J Gastroenterol 2014;33:31-4. [PMID: 23999683 DOI: 10.1007/s12664-013-0372-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
140 Lees CW, Heys D, Ho GT, Noble CL, Shand AG, Mowat C, Boulton-Jones R, Williams A, Church N, Satsangi J. A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis. Aliment Pharmacol Ther. 2007;26:411-419. [PMID: 17635376 DOI: 10.1111/j.1365-2036.2007.03383.x] [Cited by in Crossref: 94] [Cited by in F6Publishing: 82] [Article Influence: 6.3] [Reference Citation Analysis]
141 Rizzo G, Pugliese D, Armuzzi A, Coco C. Anti-TNF alpha in the treatment of ulcerative colitis: A valid approach for organ-sparing or an expensive option to delay surgery? World J Gastroenterol 2014; 20(17): 4839-4845 [PMID: 24803795 DOI: 10.3748/wjg.v20.i17.4839] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
142 Halfvarson J, Järnerot G. Treatment of choice for acute severe steroid-refractory ulcerative colitis is Remicade: . Inflammatory Bowel Diseases 2009;15:143-5. [DOI: 10.1002/ibd.20782] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
143 Danese S. Adalimumab in ulcerative colitis: Ready for prime time. Digestive and Liver Disease 2013;45:8-13. [DOI: 10.1016/j.dld.2012.05.021] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
144 Dignass A, Lindsay JO, Sturm A, Windsor A, Colombel JF, Allez M, D'Haens G, D'Hoore A, Mantzaris G, Novacek G, Oresland T, Reinisch W, Sans M, Stange E, Vermeire S, Travis S, Van Assche G. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis. 2012;6:991-1030. [PMID: 23040451 DOI: 10.1016/j.crohns.2012.09.002] [Cited by in Crossref: 657] [Cited by in F6Publishing: 574] [Article Influence: 65.7] [Reference Citation Analysis]
145 de Mattos BR, Garcia MP, Nogueira JB, Paiatto LN, Albuquerque CG, Souza CL, Fernandes LG, Tamashiro WM, Simioni PU. Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments. Mediators Inflamm. 2015;2015:493012. [PMID: 26339135 DOI: 10.1155/2015/493012] [Cited by in Crossref: 83] [Cited by in F6Publishing: 71] [Article Influence: 11.9] [Reference Citation Analysis]
146 Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E, Bianchi Porro G. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut. 2006;55:47-53. [PMID: 15972298 DOI: 10.1136/gut.2005.068809] [Cited by in Crossref: 354] [Cited by in F6Publishing: 318] [Article Influence: 20.8] [Reference Citation Analysis]
147 Woodruff TM, Arumugam TV, Shiels IA, Reid RC, Fairlie DP, Taylor SM. A potent human C5a receptor antagonist protects against disease pathology in a rat model of inflammatory bowel disease. J Immunol. 2003;171:5514-5520. [PMID: 14607958 DOI: 10.4049/jimmunol.171.10.5514] [Cited by in Crossref: 84] [Cited by in F6Publishing: 79] [Article Influence: 4.7] [Reference Citation Analysis]
148 Chung PY, Cohen RD. Evolving medical therapies for ulcerative colitis. Curr Gastroenterol Rep 2001;3:464-70. [DOI: 10.1007/s11894-001-0066-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
149 Kornbluth A. Is There Still a Role for Cyclosporine in the Treatment of Inflammatory Bowel Disease? Pro Argument: . Inflammatory Bowel Diseases 2003;9:194-7. [DOI: 10.1097/00054725-200305000-00008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
150 Casellas i Jordà F. [TNF-alpha inhibitors in inflammatory bowel disease]. Med Clin (Barc) 2004;123:627-34. [PMID: 15546523 DOI: 10.1016/s0025-7753(04)74622-9] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
151 Hindryckx P, Novak G, Vande Casteele N, Laukens D, Parker C, Shackelton LM, Narula N, Khanna R, Dulai P, Levesque BG, Sandborn WJ, D'Haens G, Feagan BG, Jairath V. Review article: dose optimisation of infliximab for acute severe ulcerative colitis. Aliment Pharmacol Ther. 2017;45:617-630. [PMID: 28074618 DOI: 10.1111/apt.13913] [Cited by in Crossref: 43] [Cited by in F6Publishing: 33] [Article Influence: 8.6] [Reference Citation Analysis]
152 Andreakos E, Foxwell B, Feldmann M. Is targeting Toll-like receptors and their signaling pathway a useful therapeutic approach to modulating cytokine-driven inflammation? Immunol Rev 2004;202:250-65. [PMID: 15546398 DOI: 10.1111/j.0105-2896.2004.00202.x] [Cited by in Crossref: 123] [Cited by in F6Publishing: 116] [Article Influence: 7.2] [Reference Citation Analysis]
153 Xie F, Blackhouse G, Assasi N, Gaebel K, Robertson D, Goeree R. Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis. Cost Eff Resour Alloc 2009;7:20. [PMID: 20003364 DOI: 10.1186/1478-7547-7-20] [Cited by in Crossref: 27] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
154 Chaparro M. [Advances in the management of ulcerative colitis presented at Digestive Disease Week 2011]. Gastroenterol Hepatol 2011;34 Suppl 2:52-9. [PMID: 22330157 DOI: 10.1016/S0210-5705(11)70021-8] [Reference Citation Analysis]
155 Moss AC, Peppercorn MA. Steroid-refractory severe ulcerative colitis: what are the available treatment options? Drugs. 2008;68:1157-1167. [PMID: 18547130 DOI: 10.2165/00003495-200868090-00001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
156 Bearden CM, Agarwal A, Book BK, Vieira CA, Sidner RA, Ochs HD, Young M, Pescovitz MD. Rituximab inhibits the in vivo primary and secondary antibody response to a neoantigen, bacteriophage phiX174. Am J Transplant 2005;5:50-7. [PMID: 15636611 DOI: 10.1111/j.1600-6143.2003.00646.x] [Cited by in Crossref: 67] [Cited by in F6Publishing: 64] [Article Influence: 3.9] [Reference Citation Analysis]
157 Moore SE, McGrail KM, Peterson S, Raval MJ, Karimuddin AA, Phang PT, Bressler B, Brown CJ. Infliximab in ulcerative colitis: the impact of preoperative treatment on rates of colectomy and prescribing practices in the province of British Columbia, Canada. Dis Colon Rectum 2014;57:83-90. [PMID: 24316950 DOI: 10.1097/DCR.0000000000000003] [Cited by in Crossref: 27] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
158 MacDonald TT, Biancheri P, Sarra M, Monteleone G. What’s the next best cytokine target in IBD? Inflamm Bowel Dis. 2012;18:2180-2189. [PMID: 22508526 DOI: 10.1002/ibd.22967] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
159 Actis GC, Pellicano R, Fagoonee S, Ribaldone DG. History of Inflammatory Bowel Diseases. J Clin Med. 2019;8:1970. [PMID: 31739460 DOI: 10.3390/jcm8111970] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 10.3] [Reference Citation Analysis]
160 Su C, Lichtenstein GR. Recent developments in inflammatory bowel disease. Med Clin North Am. 2002;86:1497-1523. [PMID: 12510462 DOI: 10.1016/s0025-7125(02)00085-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
161 Lawson MM, Thomas AG, Akobeng AK. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006;CD005112. [PMID: 16856078 DOI: 10.1002/14651858.cd005112.pub2] [Cited by in Crossref: 60] [Cited by in F6Publishing: 45] [Article Influence: 3.8] [Reference Citation Analysis]
162 Bianchi V, Maconi G, Ardizzone S, Colombo E, Ferrara E, Russo A, Tenchini ML, Porro GB. Association of NOD2/CARD15 mutations on Crohn's disease phenotype in an Italian population. Eur J Gastroenterol Hepatol. 2007;19:217-223. [PMID: 17301648 DOI: 10.1097/01.meg.0000250590.84102.12] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
163 Farrell RJ, Peppercorn MA. Ulcerative colitis. Lancet. 2002;359:331-340. [PMID: 11830216 DOI: 10.1016/s0140-6736(02)07499-8] [Cited by in Crossref: 201] [Cited by in F6Publishing: 65] [Article Influence: 10.1] [Reference Citation Analysis]
164 Plevy S, Salzberg B, Van Assche G, Regueiro M, Hommes D, Sandborn W, Hanauer S, Targan S, Mayer L, Mahadevan U. A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis. Gastroenterology. 2007;133:1414-1422. [PMID: 17920064 DOI: 10.1053/j.gastro.2007.08.035] [Cited by in Crossref: 95] [Cited by in F6Publishing: 79] [Article Influence: 6.3] [Reference Citation Analysis]
165 Harbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, Kopylov U, Kucharzik T, Molnár T, Raine T, Sebastian S, de Sousa HT, Dignass A, Carbonnel F; for the European Crohn’s and Colitis Organisation [ECCO]. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. Journal of Crohn's and Colitis 2017;11:769-84. [DOI: 10.1093/ecco-jcc/jjx009] [Cited by in Crossref: 492] [Cited by in F6Publishing: 414] [Article Influence: 98.4] [Reference Citation Analysis]
166 Bryant RV, Brain O, Travis SP. Conventional drug therapy for inflammatory bowel disease. Scand J Gastroenterol. 2015;50:90-112. [PMID: 25523560 DOI: 10.3109/00365521.2014.968864] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 5.7] [Reference Citation Analysis]
167 Mocciaro F, Renna S, Orlando A, Rizzuto G, Sinagra E, Orlando E, Cottone M. Cyclosporine or infliximab as rescue therapy in severe refractory ulcerative colitis: early and long-term data from a retrospective observational study. J Crohns Colitis. 2012;6:681-686. [PMID: 22398101 DOI: 10.1016/j.crohns.2011.11.021] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 4.4] [Reference Citation Analysis]
168 Herfarth HH, Rogler G, Higgins PD. Pushing the pedal to the metal: should we accelerate infliximab therapy for patients with severe ulcerative colitis? Clin Gastroenterol Hepatol 2015;13:336-8. [PMID: 25285408 DOI: 10.1016/j.cgh.2014.09.045] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 3.1] [Reference Citation Analysis]
169 Hanauer SB, Kornbluth AA, Messick J, Rubin DT, Sandborn WJ, Sands BE. Clinical scenarios in IBD: optimizing the use of conventional and biologic agents. Inflamm Bowel Dis. 2010;16 Suppl 1:S1-S11. [PMID: 21104734 DOI: 10.1002/ibd.21529] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
170 Mărginean CO, Meliţ LE, Mocanu S, Mărginean MO. Inflammatory bowel diseases: a burden in pediatrics: Case series and a review of the literature. Medicine (Baltimore) 2017;96:e6329. [PMID: 28296755 DOI: 10.1097/MD.0000000000006329] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
171 Cao W, Cheng L, Behar J, Fiocchi C, Biancani P, Harnett KM. Proinflammatory cytokines alter/reduce esophageal circular muscle contraction in experimental cat esophagitis. Am J Physiol Gastrointest Liver Physiol. 2004;287:G1131-G1139. [PMID: 15271650 DOI: 10.1152/ajpgi.00216.2004] [Cited by in Crossref: 63] [Cited by in F6Publishing: 63] [Article Influence: 3.5] [Reference Citation Analysis]
172 Rizzello F, Gionchetti P, Venturi A, Campieri M. Review article: medical treatment of severe ulcerative colitis. Aliment Pharmacol Ther 2003;17 Suppl 2:7-10. [PMID: 12786606 DOI: 10.1046/j.1365-2036.17.s2.18.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
173 Su C, Lewis JD, Goldberg B, Brensinger C, Lichtenstein GR. A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis. Gastroenterology. 2007;132:516-526. [PMID: 17258720 DOI: 10.1053/j.gastro.2006.12.037] [Cited by in Crossref: 102] [Cited by in F6Publishing: 86] [Article Influence: 6.4] [Reference Citation Analysis]
174 Dunckley P, Jewell D. Management of acute severe colitis. Best Practice & Research Clinical Gastroenterology 2003;17:89-103. [DOI: 10.1053/bega.2002.0343] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
175 Rosenberg LN, Peppercorn MA. Efficacy and safety of drugs for ulcerative colitis. Expert Opinion on Drug Safety 2010;9:573-92. [DOI: 10.1517/14740331003639412] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
176 Vermeire S, Rutgeerts P. Novel biological strategies in inflammatory bowel diseases. Inflamm Bowel Dis 2004;10 Suppl 1:S44-51. [PMID: 15168831 DOI: 10.1097/00054725-200402001-00010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
177 Kaya B, Doñas C, Wuggenig P, Diaz OE, Morales RA, Melhem H, Hernández PP, Kaymak T, Das S, Hruz P, Franc Y, Geier F, Ayata CK, Villablanca EJ, Niess JH; Swiss IBD. Cohort Investigators. Lysophosphatidic Acid-Mediated GPR35 Signaling in CX3CR1+ Macrophages Regulates Intestinal Homeostasis. Cell Rep 2020;32:107979. [PMID: 32755573 DOI: 10.1016/j.celrep.2020.107979] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
178 Tuvlin JA, Kane SV. Novel therapies in the treatment of ulcerative colitis. Expert Opin Investig Drugs 2003;12:483-90. [PMID: 12605569 DOI: 10.1517/13543784.12.3.483] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
179 Veres G, Baldassano RN, Mamula P. Infliximab Therapy in Children and Adolescents with Inflammatory Bowel Disease: . Drugs 2007;67:1703-23. [DOI: 10.2165/00003495-200767120-00005] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
180 Hanauer SB. Medical therapy for ulcerative colitis 2004. Gastroenterology 2004;126:1582-92. [DOI: 10.1053/j.gastro.2004.02.071] [Cited by in Crossref: 120] [Cited by in F6Publishing: 101] [Article Influence: 6.7] [Reference Citation Analysis]
181 Baert F, Vermeire S, Noman M, Van Assche G, D’ Haens G, Rutgeerts P. MANAGEMENT OF ULCERATIVE COLITIS AND CROHN’S DISEASE. Acta Clinica Belgica 2014;59:304-14. [DOI: 10.1179/acb.2004.045] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
182 Ustyugova IV, Zhi L, Wu MX. Reciprocal Regulation of The Survival and Apoptosis of Th17 and Th1 Cells in The Colon: . Inflammatory Bowel Diseases 2012;18:333-43. [DOI: 10.1002/ibd.21772] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
183 Willert RP, Lawrance IC. Use of infliximab in the prevention and delay of colectomy in severe steroid dependant and refractory ulcerative colitis. World J Gastroenterol 2008; 14(16): 2544-2549 [PMID: 18442203 DOI: 10.3748/wjg.14.2544] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 24] [Article Influence: 1.5] [Reference Citation Analysis]
184 Lichtenstein GR, Abreu MT, Cohen R, Tremaine W; American Gastroenterological Association. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130:940-987. [PMID: 16530532 DOI: 10.1053/j.gastro.2006.01.048] [Cited by in Crossref: 328] [Cited by in F6Publishing: 303] [Article Influence: 20.5] [Reference Citation Analysis]
185 N/A. N/A. Shijie Huaren Xiaohua Zazhi 2004; 12(6): 1441-1444 [DOI: 10.11569/wcjd.v12.i6.1441] [Reference Citation Analysis]
186 Ardizzone S, Bianchi Porro G. Biologic Therapy for Inflammatory Bowel Disease: . Drugs 2005;65:2253-86. [DOI: 10.2165/00003495-200565160-00002] [Cited by in Crossref: 178] [Cited by in F6Publishing: 178] [Article Influence: 10.5] [Reference Citation Analysis]
187 Komaki Y, Komaki F, Micic D, Yamada A, Suzuki Y, Sakuraba A. Pharmacologic therapies for severe steroid refractory hospitalized ulcerative colitis: A network meta-analysis. J Gastroenterol Hepatol. 2017;32:1143-1151. [PMID: 27957761 DOI: 10.1111/jgh.13674] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
188 Castro Fernández M, García Díaz E, Romero M, Galán Jurado V, Rodríguez Alonso C. Tratamiento de la colitis ulcerosa corticorrefractaria con infliximab. Gastroenterología y Hepatología 2003;26:54-5. [DOI: 10.1016/s0210-5705(03)70344-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
189 Thorlund K, Druyts E, Mills EJ, Fedorak RN, Marshall JK. Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naïve to anti-TNF therapy: an indirect treatment comparison meta-analysis. J Crohns Colitis. 2014;8:571-581. [PMID: 24491514 DOI: 10.1016/j.crohns.2014.01.010] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 5.9] [Reference Citation Analysis]
190 Lv R, Qiao W, Wu Z, Wang Y, Dai S, Liu Q, Zheng X. Tumor necrosis factor alpha blocking agents as treatment for ulcerative colitis intolerant or refractory to conventional medical therapy: a meta-analysis. PLoS One. 2014;9:e86692. [PMID: 24475168 DOI: 10.1371/journal.pone.0086692] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 3.8] [Reference Citation Analysis]
191 Aggarwal A, Sabol T, Vaziri H. Update on the Use of Biologic Therapy in Ulcerative Colitis. Curr Treat Options Gastroenterol 2017;15:155-67. [PMID: 28120279 DOI: 10.1007/s11938-017-0120-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
192 Su C, Salzberg BA, Lewis JD, Deren JJ, Kornbluth A, Katzka DA, Stein RB, Adler DR, Lichtenstein GR. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol. 2002;97:2577-2584. [PMID: 12385442 DOI: 10.1111/j.1572-0241.2002.06026.x] [Cited by in Crossref: 126] [Cited by in F6Publishing: 111] [Article Influence: 6.3] [Reference Citation Analysis]
193 Ross H, Steele SR, Varma M, Dykes S, Cima R, Buie WD, Rafferty J. Practice parameters for the surgical treatment of ulcerative colitis. Dis Colon Rectum. 2014;57:5-22. [PMID: 24316941 DOI: 10.1097/dcr.0000000000000030] [Cited by in Crossref: 107] [Cited by in F6Publishing: 27] [Article Influence: 13.4] [Reference Citation Analysis]
194 Seksik P, Contou JF, Ducrotté P, Faucheron JL, de Parades V. [The treatment of distal ulcerative colitis]. Gastroenterol Clin Biol 2004;28:964-73. [PMID: 15672568 DOI: 10.1016/s0399-8320(04)95174-3] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
195 Hindryckx P, Jairath V, D'Haens G. Acute severe ulcerative colitis: from pathophysiology to clinical management. Nat Rev Gastroenterol Hepatol. 2016;13:654-664. [PMID: 27580687 DOI: 10.1038/nrgastro.2016.116] [Cited by in Crossref: 56] [Cited by in F6Publishing: 49] [Article Influence: 9.3] [Reference Citation Analysis]
196 Mahadevan U. Medical treatment of ulcerative colitis. Clin Colon Rectal Surg. 2004;17:7-19. [PMID: 20011280 DOI: 10.1055/s-2004-823066] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
197 Gornet J, Couve S, Hassani Z, Delchier J, Marteau P, Cosnes J, Bouhnik Y, Dupas J, Modigliani R, Taillard F, Lemann M. Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre study: INFLIXIMAB FOR REFRACTORY ULCERATIVE COLITIS. Alimentary Pharmacology & Therapeutics 2003;18:175-81. [DOI: 10.1046/j.1365-2036.2003.01686.x] [Cited by in Crossref: 76] [Cited by in F6Publishing: 67] [Article Influence: 4.0] [Reference Citation Analysis]
198 Song Y, Zheng P. Efficacy and safety of tumor necrosis factor-α blockers for ulcerative colitis: A systematic review and meta-analysis of published randomized controlled trials. Journal of Food and Drug Analysis 2015;23:1-10. [DOI: 10.1016/j.jfda.2014.06.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
199 Sartor RB, Hoentjen F. Proinflammatory Cytokines and Signaling Pathways in Intestinal Innate Immune Cells. Mucosal Immunology. Elsevier; 2005. pp. 681-701. [DOI: 10.1016/b978-012491543-5/50039-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
200 Masson S, Nylander D, Mansfield JC. How important is onset of action in ulcerative colitis therapy? Drugs. 2005;65:2069-2083. [PMID: 16225364 DOI: 10.2165/00003495-200565150-00001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
201 Targownik LE, Bernstein CN. Infectious and malignant complications of TNF inhibitor therapy in IBD. Am J Gastroenterol. 2013;108:1835-1842, quiz 1843. [PMID: 24042192 DOI: 10.1038/ajg.2013.294] [Cited by in Crossref: 71] [Cited by in F6Publishing: 64] [Article Influence: 7.9] [Reference Citation Analysis]
202 Verdon C, Bessissow T, Lakatos PL. Management of Acute Severe Colitis in the Era of Biologicals and Small Molecules. J Clin Med 2019;8:E2169. [PMID: 31817972 DOI: 10.3390/jcm8122169] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
203 Ochsenkühn T, Sackmann M, Göke B. Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study. European Journal of Gastroenterology & Hepatology 2004;16:1167-71. [DOI: 10.1097/00042737-200411000-00014] [Cited by in Crossref: 84] [Cited by in F6Publishing: 74] [Article Influence: 4.7] [Reference Citation Analysis]
204 Jürgens M, Laubender RP, Hartl F, Weidinger M, Seiderer J, Wagner J, Wetzke M, Beigel F, Pfennig S, Stallhofer J. Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis. Am J Gastroenterol. 2010;105:1811-1819. [PMID: 20197757 DOI: 10.1038/ajg.2010.95] [Cited by in Crossref: 110] [Cited by in F6Publishing: 107] [Article Influence: 9.2] [Reference Citation Analysis]
205 Law JK, Salh B, Yoshida EM. All that bleeds is not infliximab-refractory ulcerative colitis. Can J Gastroenterol 2009;23:91-2. [PMID: 19214282 DOI: 10.1155/2009/983121] [Reference Citation Analysis]
206 Barberio B, Black CJ, Savarino EV, Ford AC. Ciclosporin or Infliximab as Rescue Therapy in Acute Glucorticosteroid-Refractory Ulcerative Colitis: Systematic Review and Network Meta-Analysis. J Crohns Colitis 2021;15:733-41. [PMID: 33175102 DOI: 10.1093/ecco-jcc/jjaa226] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
207 Mamula P, Markowitz JE, Cohen LJ, von Allmen D, Baldassano RN. Infliximab in pediatric ulcerative colitis: two-year follow-up. J Pediatr Gastroenterol Nutr. 2004;38:298-301. [PMID: 15076630 DOI: 10.1097/00005176-200403000-00013] [Cited by in Crossref: 66] [Cited by in F6Publishing: 52] [Article Influence: 3.9] [Reference Citation Analysis]
208 Lopez A, Ford AC, Colombel JF, Reinisch W, Sandborn WJ, Peyrin-Biroulet L. Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: Meta-analysis of placebo-controlled trials. Dig Liver Dis. 2015;47:356-364. [PMID: 25661014 DOI: 10.1016/j.dld.2015.01.148] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
209 Wilhelm SM, McKenney KA, Rivait KN, Kale-Pradhan PB. A review of infliximab use in ulcerative colitis. Clin Ther. 2008;30:223-230. [PMID: 18343261 DOI: 10.1016/j.clinthera.2008.02.014] [Cited by in Crossref: 31] [Cited by in F6Publishing: 36] [Article Influence: 2.4] [Reference Citation Analysis]
210 Sandborn WJ. Strategies for targeting tumour necrosis factor in IBD. Best Practice & Research Clinical Gastroenterology 2003;17:105-17. [DOI: 10.1053/bega.2002.0345] [Cited by in Crossref: 60] [Cited by in F6Publishing: 61] [Article Influence: 3.2] [Reference Citation Analysis]
211 Sands BE. New therapies for the treatment of inflammatory bowel disease. Surg Clin North Am. 2006;86:1045-1064. [PMID: 16905423 DOI: 10.1016/j.suc.2006.05.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
212 Díez M, Sánchez E, García López S, Teresa Arroyo M, Gomollón F. Tratamiento con infliximab en la colitis ulcerosa: experiencia inicial en dos centros de referencia. Gastroenterología y Hepatología 2007;30:449-53. [DOI: 10.1157/13110489] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
213 Ebrahimi Daryani N, Najmi Varzaneh F, Hedayat M, Taher M, Farhadi E, Mahmoudi M, Nicknam MH, Bashashati M, Rezaei N. Interleukin-23 receptor single nucleotide polymorphisms in ulcerative colitis. A study in Iranian populations. Clinics and Research in Hepatology and Gastroenterology 2014;38:360-5. [DOI: 10.1016/j.clinre.2013.12.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
214 Shen EH, Das KM. Current therapeutic recommendations: infliximab for ulcerative colitis. J Clin Gastroenterol 2004;38:741-5. [PMID: 15365397 DOI: 10.1097/01.mcg.0000140188.88275.65] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
215 Brown SR, Haboubi N, Hampton J, George B, Travis SP. The management of acute severe colitis: ACPGBI position statement. Colorectal Dis. 2008;10 Suppl 3:8-29. [PMID: 18954307 DOI: 10.1111/j.1463-1318.2008.01682.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
216 Schleyer V, Landthaler M, Szeimies R. Novel pharmacological approaches in the treatment of psoriasis. J Eur Acad Dermatol Venerol 2005;19:1-20. [DOI: 10.1111/j.1468-3083.2004.01070.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
217 Braun J, Brandt J, Listing J, Rudwaleit M, Sieper J. Biologic therapies in the spondyloarthritis: new opportunities, new challenges. Curr Opin Rheumatol 2003;15:394-407. [PMID: 12819466 DOI: 10.1097/00002281-200307000-00005] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
218 Beaugerie L, Blain A, Brazier F, Gornet J, Parc Y. Traitement de la rectocolite ulcéro-hémorragique dans sa forme étendue (colite grave exclue). Gastroentérologie Clinique et Biologique 2004;28:974-83. [DOI: 10.1016/s0399-8320(04)95175-5] [Cited by in Crossref: 4] [Article Influence: 0.2] [Reference Citation Analysis]
219 Punekar YS, Hawkins N. Cost-effectiveness of infliximab for the treatment of acute exacerbations of ulcerative colitis. Eur J Health Econ. 2010;11:67-76. [PMID: 19844750 DOI: 10.1007/s10198-009-0199-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 1.9] [Reference Citation Analysis]
220 Modigliani R. Medical Management of Fulminant Colitis: . Inflammatory Bowel Diseases 2002;8:129-34. [DOI: 10.1097/00054725-200203000-00009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
221 Panaccione R, Fedorak RN, Aumais G, Bernard EJ, Bernstein CN, Bitton A, Croitoru K, Dieleman LA, Enns R, Feagan BG, Franchimont D, Greenberg GR, Griffiths AM, Marshall JK, Pare P, Patel S, Penner R, Render C, Seidman E, Steinhart AH. Review and clinical perspectives for the use of infliximab in ulcerative colitis. Can J Gastroenterol 2008;22:261-72. [PMID: 18354755 DOI: 10.1155/2008/493405] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
222 Billiet T, Rutgeerts P, Ferrante M, Van Assche G, Vermeire S. Targeting TNF-α for the treatment of inflammatory bowel disease. Expert Opinion on Biological Therapy 2013;14:75-101. [DOI: 10.1517/14712598.2014.858695] [Cited by in Crossref: 85] [Cited by in F6Publishing: 88] [Article Influence: 9.4] [Reference Citation Analysis]
223 Marchioni Beery R, Kane S. Current approaches to the management of new-onset ulcerative colitis. Clin Exp Gastroenterol. 2014;7:111-132. [PMID: 24872716 DOI: 10.2147/ceg.s35942] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
224 Bewtra M, Lichtenstein GR. Infliximab use in Crohn’s disease. Expert Opinion on Biological Therapy 2005;5:589-99. [DOI: 10.1517/14712598.5.4.589] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
225 Fuss IJ. Treatment of Ulcerative Colitis with Infliximab: Are We There Yet?: . Journal of Pediatric Gastroenterology and Nutrition 2004;38:247-9. [DOI: 10.1097/00005176-200403000-00005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
226 Fanjiang G, Russell GH, Katz AJ. Short- and Long-term Response to and Weaning from Infliximab Therapy in Pediatric Ulcerative Colitis. Journal of Pediatric Gastroenterology & Nutrition 2007;44:312-7. [DOI: 10.1097/mpg.0b013e31802e98d4] [Cited by in Crossref: 44] [Cited by in F6Publishing: 15] [Article Influence: 2.9] [Reference Citation Analysis]
227 Shah B, Mayer L. Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease. Expert Rev Clin Immunol 2010;6:607-20. [PMID: 20594134 DOI: 10.1586/eci.10.45] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
228 Katz JA. Advances in the medical therapy of inflammatory bowel disease. Curr Opin Gastroenterol 2002;18:435-40. [PMID: 17033318 DOI: 10.1097/00001574-200207000-00007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
229 Sandborn WJ, Faubion WA. Biologics in inflammatory bowel disease: how much progress have we made? Gut 2004;53:1366-73. [PMID: 15306602 DOI: 10.1136/gut.2003.025452] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 2.3] [Reference Citation Analysis]
230 Regueiro M, Curtis J, Plevy S. Infliximab for hospitalized patients with severe ulcerative colitis. J Clin Gastroenterol 2006;40:476-81. [PMID: 16825928 DOI: 10.1097/00004836-200607000-00004] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 3.3] [Reference Citation Analysis]
231 Minami N, Yoshino T, Matsuura M, Koshikawa Y, Yamada S, Toyonaga T, Madian A, Honzawa Y, Nakase H. Tacrolimus or infliximab for severe ulcerative colitis: short-term and long-term data from a retrospective observational study. BMJ Open Gastroenterol. 2015;2:e000021. [PMID: 26462273 DOI: 10.1136/bmjgast-2014-000021] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
232 Bressler B, Law JK, Al Nahdi Sheraisher N, Atkinson K, Byrne MF, Chung HV, Fishman M, Partovi N, Pearson D, Penner R, Enns RA. The use of infliximab for treatment of hospitalized patients with acute severe ulcerative colitis. Can J Gastroenterol 2008;22:937-40. [PMID: 19018340 DOI: 10.1155/2008/749547] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
233 Rosen MJ, Minar P, Vinks AA. Review article: applying pharmacokinetics to optimise dosing of anti-TNF biologics in acute severe ulcerative colitis. Aliment Pharmacol Ther. 2015;41:1094-1103. [PMID: 25809869 DOI: 10.1111/apt.13175] [Cited by in Crossref: 63] [Cited by in F6Publishing: 47] [Article Influence: 9.0] [Reference Citation Analysis]
234 Samaan MA, Bagi P, Vande Casteele N, D’haens GR, Levesque BG. An Update on Anti-TNF Agents in Ulcerative Colitis. Gastroenterology Clinics of North America 2014;43:479-94. [DOI: 10.1016/j.gtc.2014.05.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
235 Halpin SJ, Hamlin PJ, Greer DP, Warren L, Ford AC. Efficacy of infliximab in acute severe ulcerative colitis: A single-centre experience. World J Gastroenterol 2013; 19(7): 1091-1097 [PMID: 23467174 DOI: 10.3748/wjg.v19.i7.1091] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
236 Braun J, Sieper J. Overview of the use of the anti-TNF agent infliximab in chronic inflammatory diseases. Expert Opin Biol Ther 2003;3:141-68. [PMID: 12718738 DOI: 10.1517/14712598.3.1.141] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
237 Choy MC, Seah D, Faleck DM, Shah SC, Chao CY, An YK, Radford-Smith G, Bessissow T, Dubinsky MC, Ford AC, Churilov L, Yeomans ND, De Cruz PP. Systematic Review and Meta-analysis: Optimal Salvage Therapy in Acute Severe Ulcerative Colitis. Inflamm Bowel Dis 2019;25:1169-86. [PMID: 30605549 DOI: 10.1093/ibd/izy383] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 13.5] [Reference Citation Analysis]
238 Targan SR, Karp LC. Defects in mucosal immunity leading to ulcerative colitis. Immunol Rev. 2005;206:296-305. [PMID: 16048556 DOI: 10.1111/j.0105-2896.2005.00286.x] [Cited by in Crossref: 116] [Cited by in F6Publishing: 110] [Article Influence: 6.8] [Reference Citation Analysis]
239 Archer R, Tappenden P, Ren S, Martyn-St James M, Harvey R, Basarir H, Stevens J, Carroll C, Cantrell A, Lobo A, Hoque S. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model. Health Technol Assess 2016;20:1-326. [PMID: 27220829 DOI: 10.3310/hta20390] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 5.5] [Reference Citation Analysis]
240 Kornbluth A, Sachar DB;  Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105:501-23; quiz 524. [PMID: 20068560 DOI: 10.1038/ajg.2009.727] [Cited by in Crossref: 826] [Cited by in F6Publishing: 730] [Article Influence: 68.8] [Reference Citation Analysis]
241 Stokkers PC, Hommes DW. Novel biological therapies for inflammatory bowel disease. Curr Treat Options Gastroenterol 2006;9:201-10. [PMID: 16901384 DOI: 10.1007/s11938-006-0039-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
242 Kumar A, Auron M, Aneja A, Mohr F, Jain A, Shen B. Inflammatory bowel disease: perioperative pharmacological considerations. Mayo Clin Proc. 2011;86:748-757. [PMID: 21803957 DOI: 10.4065/mcp.2011.0074] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
243 Wong U, Cross RK. Primary and secondary nonresponse to infliximab: mechanisms and countermeasures. Expert Opin Drug Metab Toxicol 2017;13:1039-46. [PMID: 28876147 DOI: 10.1080/17425255.2017.1377180] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 5.6] [Reference Citation Analysis]
244 Sands BE, Kaplan GG. The role of TNFalpha in ulcerative colitis. J Clin Pharmacol. 2007;47:930-941. [PMID: 17567930 DOI: 10.1177/0091270007301623] [Cited by in Crossref: 84] [Cited by in F6Publishing: 89] [Article Influence: 5.6] [Reference Citation Analysis]
245 Mor IJ, Vogel JD, da Luz Moreira A, Shen B, Hammel J, Remzi FH. Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy. Dis Colon Rectum. 2008;51:1202-1207; discussion 1202-1210. [PMID: 18536964 DOI: 10.1007/s10350-008-9364-7] [Cited by in Crossref: 204] [Cited by in F6Publishing: 160] [Article Influence: 14.6] [Reference Citation Analysis]
246 Shi N, Clinton SK, Liu Z, Wang Y, Riedl KM, Schwartz SJ, Zhang X, Pan Z, Chen T. Strawberry phytochemicals inhibit azoxymethane/dextran sodium sulfate-induced colorectal carcinogenesis in Crj: CD-1 mice. Nutrients 2015;7:1696-715. [PMID: 25763529 DOI: 10.3390/nu7031696] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 6.9] [Reference Citation Analysis]
247 Barreiro-de Acosta M, Lorenzo A, Mera J, Dominguez-Muñoz JE. Mucosal healing and steroid-sparing associated with infliximab for steroid-dependent ulcerative colitis. J Crohns Colitis 2009;3:271-6. [PMID: 21172286 DOI: 10.1016/j.crohns.2009.06.003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
248 Nelson R, Liao C, Fichera A, Rubin DT, Pekow J. Rescue therapy with cyclosporine or infliximab is not associated with an increased risk for postoperative complications in patients hospitalized for severe steroid-refractory ulcerative colitis. Inflamm Bowel Dis 2014;20:14-20. [PMID: 24297054 DOI: 10.1097/01.MIB.0000437497.07181.05] [Cited by in Crossref: 33] [Cited by in F6Publishing: 16] [Article Influence: 4.1] [Reference Citation Analysis]
249 D’Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, Lémann M, Marteau P, Rutgeerts P, Schölmerich J. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132:763-786. [PMID: 17258735 DOI: 10.1053/j.gastro.2006.12.038] [Cited by in Crossref: 629] [Cited by in F6Publishing: 562] [Article Influence: 39.3] [Reference Citation Analysis]
250 Actis GC, Bruno M, Pinna-Pintor M, Rossini FP, Rizzetto M. Infliximab for treatment of steroid-refractory ulcerative colitis. Dig Liver Dis. 2002;34:631-634. [PMID: 12405249 DOI: 10.1016/s1590-8658(02)80205-5] [Cited by in Crossref: 51] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
251 Ackermann C, Kavanaugh A. Tumor necrosis factor as a therapeutic target of rheumatologic disease. Expert Opin Ther Targets 2007;11:1369-84. [PMID: 18028004 DOI: 10.1517/14728222.11.11.1369] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 3.0] [Reference Citation Analysis]
252 O'Donnell S, Stempak JM, Steinhart AH, Silverberg MS. Higher Rates of Dose Optimisation for Infliximab Responders in Ulcerative Colitis than in Crohn's disease. J Crohns Colitis. 2015;9:830-836. [PMID: 26116556 DOI: 10.1093/ecco-jcc/jjv115] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
253 Oussalah A, Laclotte C, Chevaux JB, Bensenane M, Babouri A, Serre AA, Boucekkine T, Roblin X, Bigard MA, Peyrin-Biroulet L. Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience. Aliment Pharmacol Ther 2008;28:966-72. [PMID: 18652603 DOI: 10.1111/j.1365-2036.2008.03811.x] [Cited by in Crossref: 62] [Cited by in F6Publishing: 54] [Article Influence: 4.4] [Reference Citation Analysis]
254 Mack DR, Beedle S, Warren J, Davis J, Gross T. Peripheral Blood Intracellular Cytokine Analysis in Children Newly Diagnosed with Inflammatory Bowel Disease. Pediatr Res 2002;51:328-32. [DOI: 10.1203/00006450-200203000-00011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
255 Simmons J, Jewell D. Infliximab for ulcerative colitis. Digestive and Liver Disease 2002;34:616-8. [DOI: 10.1016/s1590-8658(02)80201-8] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
256 Choi CH, Kim Y, Kim YS, Ye BD, Lee KM, Lee BI, Jung S, Kim WH, Lee H; IBD Study Group of the Korean Association for the Study of Intestinal Diseases. Guidelines for the Management of Ulcerative Colitis. Intest Res 2012;10:1. [DOI: 10.5217/ir.2012.10.1.1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
257 Tsiodras S, Samonis G, Boumpas DT, Kontoyiannis DP. Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc. 2008;83:181-194. [PMID: 18241628 DOI: 10.1016/s0025-6196(11)60839-2] [Cited by in Crossref: 196] [Cited by in F6Publishing: 2] [Article Influence: 14.0] [Reference Citation Analysis]
258 Kugathasan S, Dubinsky MC, Keljo D, Moyer MS, Rufo PA, Wyllie R, Zachos M, Hyams J. Severe Colitis in Children: . Journal of Pediatric Gastroenterology and Nutrition 2005;41:375-85. [DOI: 10.1097/01.mpg.0000186272.65559.ce] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
259 Narula N, Jharap B, Colombel J. Management of Severe Ulcerative Colitis. Curr Treat Options Gastro 2015;13:59-76. [DOI: 10.1007/s11938-014-0036-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
260 Solem CA, Loftus EV Jr. Management of refractory inflammatory bowel disease. Gastroenterol Clin North Am 2004;33:319-34, x. [PMID: 15177541 DOI: 10.1016/j.gtc.2004.02.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
261 Sandborn WJ, Loftus EV. Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease. Gut 2004;53:780-2. [PMID: 15138201 DOI: 10.1136/gut.2003.020552] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 2.7] [Reference Citation Analysis]
262 Doherty GA, Cheifetz AS. Management of acute severe ulcerative colitis. Expert Review of Gastroenterology & Hepatology 2014;3:395-405. [DOI: 10.1586/egh.09.24] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
263 Puthoor PR, de Zoeten EF. Pediatric Ulcerative Colitis: The Therapeutic Road to Infliximab. Biol Ther. 2013;3:1-14. [PMID: 24392300 DOI: 10.1007/s13554-012-0006-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
264 Rutgeerts P, Van Assche G, Vermeire S. Review article: Infliximab therapy for inflammatory bowel disease--seven years on. Aliment Pharmacol Ther. 2006;23:451-463. [PMID: 16441465 DOI: 10.1111/j.1365-2036.2006.02786.x] [Cited by in Crossref: 168] [Cited by in F6Publishing: 162] [Article Influence: 10.5] [Reference Citation Analysis]
265 Braun J, van der Heijde D. Novel approaches in the treatment of ankylosing spondylitis and other spondyloarthritides. Expert Opinion on Investigational Drugs 2005;12:1097-109. [DOI: 10.1517/13543784.12.7.1097] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 1.5] [Reference Citation Analysis]
266 Durai D, Hawthorne AB. Review article: how and when to use ciclosporin in ulcerative colitis. Aliment Pharmacol Ther 2005;22:907-16. [PMID: 16268964 DOI: 10.1111/j.1365-2036.2005.02680.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 1.7] [Reference Citation Analysis]
267 Gustavsson A, Järnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlén P, Grännö C, Vilien M, Ström M, Verbaan H. Clinical trial: colectomy after rescue therapy in ulcerative colitis - 3-year follow-up of the Swedish-Danish controlled infliximab study. Aliment Pharmacol Ther. 2010;32:984-989. [PMID: 20937043 DOI: 10.1111/j.1365-2036.2010.04435.x] [Cited by in Crossref: 127] [Cited by in F6Publishing: 113] [Article Influence: 10.6] [Reference Citation Analysis]
268 Katz JA. Management of inflammatory bowel disease in adults. J Dig Dis 2007;8:65-71. [PMID: 17532817 DOI: 10.1111/j.1443-9573.2007.00287.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
269 Sandhu BK, Fell JM, Beattie RM, Mitton SG, Wilson DC, Jenkins H; IBD Working Group of the British Society of Paediatric Gastroenterology, Hepatology, and Nutrition. Guidelines for the management of inflammatory bowel disease in children in the United Kingdom. J Pediatr Gastroenterol Nutr 2010;50 Suppl 1:S1-13. [PMID: 20081543 DOI: 10.1097/MPG.0b013e3181c92c53] [Cited by in Crossref: 101] [Cited by in F6Publishing: 30] [Article Influence: 11.2] [Reference Citation Analysis]
270 Cohen RD. Evolving medical therapies for ulcerative colitis. Curr Gastroenterol Rep 2002;4:497-505. [DOI: 10.1007/s11894-002-0026-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
271 Gionchetti P, Rizzello F, Annese V, Armuzzi A, Biancone L, Castiglione F, Comberlato M, Cottone M, Danese S, Daperno M, D'Incà R, Fries W, Kohn A, Orlando A, Papi C, Vecchi M, Ardizzone S; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease.Dig Liver Dis. 2017;49:604-617. [PMID: 28254463 DOI: 10.1016/j.dld.2017.01.161] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 5.6] [Reference Citation Analysis]
272 Shah SC, Naymagon S, Panchal HJ, Sands BE, Cohen BL, Dubinsky MC. Accelerated Infliximab Dosing Increases 30-Day Colectomy in Hospitalized Ulcerative Colitis Patients: A Propensity Score Analysis. Inflamm Bowel Dis 2018;24:651-9. [PMID: 29462380 DOI: 10.1093/ibd/izx039] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 7.7] [Reference Citation Analysis]
273 Dubinsky MC. Reviewing treatments and outcomes in the evolving landscape of ulcerative colitis. Postgraduate Medicine 2017;129:538-53. [DOI: 10.1080/00325481.2017.1319730] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
274 Wang Q, Wen Z, Cao Q. Risk of tuberculosis during infliximab therapy for inflammatory bowel disease, rheumatoid arthritis, and spondyloarthropathy: A meta-analysis. Exp Ther Med 2016;12:1693-704. [PMID: 27588089 DOI: 10.3892/etm.2016.3548] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]